🟢 Tiziana Life Sciences is trading 13.45% up in pre-market after 50 μg dose reduced microglial activation

Tiziana Life Sciences is trading at $0.78, up 13.45% in pre-market after the 50 μg dose reduced microglial activation versus placebo in its Phase 2a INFORM-MS trial.

• The company reported positive topline results on November 2; both doses met safety goals.
• The higher dose did not meet the imaging endpoint.
• The company plans further analysis and FDA discussions; no separate November 4 announcement was identified.